New genes added to our preset, focus, and comprehensive panels.
Comprehensive Cancer Panel: CTNNA1, GREM1, NTHL1, SLC45A2
Focus Cancer Panel: GREM1
Typical coverage for coding sequences: 99% at ≥ 50x
Deletion and duplication analysis with single exon resolution for all genes
BRCA2: Portuguese Founder Mutation
PTEN: Promoter region
TP53: Promoter region
CDKN2A: p14ARF and p16 protein products
PMS2: Analysis includes exons 1-5 and 12-15
TERT: Promoter region
GREM1: Promoter region
Fulgent Focus Cancer Panels target 30 genes associated with high/moderate risk for hereditary cancer syndromes and established clinical management guidelines for disease-causing variants. These panels provide the most optimal balance between detection of pathogenic cancer susceptibility mutations, and minimizing the number of reported variants of unknown clinical significance.
Fulgent Comprehensive Cancer Panels cover 127 genes associated with potential risk for hereditary cancer syndromes. These panels include well-established cancer-related genes as well as candidate genes with newly discovered association with cancer, but may have reduced or unclear risk. Hereditary cancer syndromes with complex presentations may benefit from more comprehensive testing. Fulgent Comprehensive Cancer Panels maximize the chance of identifying disease-causing variants and provide an extensive review of potential cancer risks from additional candidate genes.
Panel Coverage: ~99% at 50x
Deletion / Duplication: ≥ 1 exon
Sequencing Methods: NGS
Orthogonal Methods: Sanger, qPCR, MLPA
Turnaround Time: 2-3 weeks